No Data
No Data
Zhaoyun International: The Pharmaceutical price policy is expected to be optimized, and FSG Medical Serv A is accelerating commercialization.
Zhao Yin International's valuation repair in the Pharmaceutical Industry.
Guosen: Focus on AI + Medical, high-quality innovation, and value symbols with stable performance.
Guosen remains bullish on companies with differentiated innovation capabilities and overseas potential.
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy
SKB BIO-B (06990.HK) established a market management service agreement with Kelong Jialin.
SKB BIO-B (06990.HK) announced that on February 12, 2025, the company entered into a market management service framework agreement with Corun Jiaxun, under which Corun Jiaxun and/or its affiliates will provide market management services to the company for the research and development of the recombinant epidermal growth factor receptor (EGFR) human-mouse chimeric monoclonal antibody (monoclonal antibody) Cetuximab N01 injection (formerly A140) (Datalay).
SKB Biotech Biopharma to Present Results of Phase 1/2 Study of Cancer Drug at US Oncology Meeting
[Hong Kong Stock Connect] Kelun-Botai Biopharmaceutical (06990) will announce the research results of its core products at the USA Clinical Oncology Society Cancer Conference.
Jinwu Financial News | Cerenbo Tai Biological (06990) announced that the company will present its antibody-drug conjugate (ADC) sac-TMT (formerly known as SKB264/MK-2870) targeting tumor-associated calcium signal transducer 2 (TROP2) at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium to be held from February 13 to 15, 2025. This will be for the treatment of patients with unresectable, locally advanced, or metastatic urothelial carcinoma (UC) who have previously received anticancer therapy or have experienced disease progression after treatment.